PE20231814A1 - Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y metodos para su uso - Google Patents

Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y metodos para su uso

Info

Publication number
PE20231814A1
PE20231814A1 PE2023002212A PE2023002212A PE20231814A1 PE 20231814 A1 PE20231814 A1 PE 20231814A1 PE 2023002212 A PE2023002212 A PE 2023002212A PE 2023002212 A PE2023002212 A PE 2023002212A PE 20231814 A1 PE20231814 A1 PE 20231814A1
Authority
PE
Peru
Prior art keywords
optionally substituted
methyl
methods
pharmaceutical compositions
receptor agonists
Prior art date
Application number
PE2023002212A
Other languages
English (en)
Spanish (es)
Inventor
Xiaohui Du
Ray Fucini
Xu Ran
Chien-Hung Yeh
Xiang Zhou
Rui Gao
Joon Won Jeong
Li Liu
Subas Man Sakya
Xiaofang Wang
Hiroyuki Kawai
Craig Lee
David Lloyd
Stig Hansen
Original Assignee
Carmot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmot Therapeutics Inc filed Critical Carmot Therapeutics Inc
Publication of PE20231814A1 publication Critical patent/PE20231814A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2023002212A 2021-01-28 2022-01-27 Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y metodos para su uso PE20231814A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163143025P 2021-01-28 2021-01-28
US202163183612P 2021-05-03 2021-05-03
US202163274893P 2021-11-02 2021-11-02
PCT/US2022/014156 WO2022165076A1 (en) 2021-01-28 2022-01-27 Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use

Publications (1)

Publication Number Publication Date
PE20231814A1 true PE20231814A1 (es) 2023-11-16

Family

ID=80447497

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002212A PE20231814A1 (es) 2021-01-28 2022-01-27 Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y metodos para su uso

Country Status (18)

Country Link
US (4) US20240252492A1 (cg-RX-API-DMAC10.html)
EP (2) EP4284795A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024505250A (cg-RX-API-DMAC10.html)
KR (1) KR20230152011A (cg-RX-API-DMAC10.html)
CN (1) CN122344190A (cg-RX-API-DMAC10.html)
AU (1) AU2022212019A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023015045A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209593A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023002204A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023011071A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230330A (cg-RX-API-DMAC10.html)
EC (1) ECSP23057029A (cg-RX-API-DMAC10.html)
GE (2) GEAP202616925A (cg-RX-API-DMAC10.html)
IL (1) IL304521B1 (cg-RX-API-DMAC10.html)
JO (1) JOP20230167A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023008854A (cg-RX-API-DMAC10.html)
PE (1) PE20231814A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022165076A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
KR20240053617A (ko) 2021-08-30 2024-04-24 민드랭크 에이아이 리미티드 Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
WO2023057427A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20250236627A1 (en) 2021-10-05 2025-07-24 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN117362282B (zh) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
IL318410A (en) * 2022-07-18 2025-03-01 Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd Polymorphic form of GLP-1R agonist, method of preparation thereof and use thereof
CN119923395A (zh) * 2022-07-27 2025-05-02 卡莫特医疗有限公司 N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法
WO2024051700A1 (zh) * 2022-09-05 2024-03-14 德睿智药(苏州)新药研发有限公司 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物
JP2025530809A (ja) * 2022-09-06 2025-09-17 徳睿智薬（蘇州）新薬研発有限公司 Ｇｌｐ－１ｒアゴニスト化合物の結晶多形物及びその製造方法と使用
CN116102543B (zh) * 2022-10-21 2025-07-22 江南大学 一种glp-1r激动剂、合成方法及其用途
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
CR20250178A (es) 2022-11-16 2025-06-06 Lilly Co Eli Agonistas del receptor del péptido-1 similar al glucagón
EP4638455A1 (en) * 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120693333A (zh) * 2023-01-19 2025-09-23 杭州德睿智药科技有限公司 Glp-1r激动剂的制造方法与中间体及其用途
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025128561A1 (en) 2023-12-11 2025-06-19 Carmot Therapeutics, Inc. Crystalline forms of a glp-1 receptor modulator
CN122374306A (zh) 2023-12-11 2026-07-10 卡莫特医疗有限公司 Glp-1受体调节剂的盐型
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2025259888A1 (en) 2024-06-13 2025-12-18 Carmot Therapeutics Inc. Method of treating diabetes using a glp-1 receptor agonist
WO2026047102A1 (en) 2024-08-29 2026-03-05 F. Hoffmann-La Roche Ag Process for the preparation of pyrimidine derivatives
WO2026162461A1 (en) 2025-01-29 2026-08-06 F. Hoffmann-La Roche Ag A glp-1 receptor modulator for use in the treatment of metabolic diseases, including diabetes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109607A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3045644C (en) 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
AU2020256647B2 (en) 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
ES3029360T3 (en) * 2019-11-15 2025-06-24 Ildong Pharmaceutical Co Ltd Glp-1 receptor agonist and use thereof
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021219019A1 (en) * 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2023538408A (ja) * 2020-08-21 2023-09-07 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒ作動薬としての化合物
JP2023538949A (ja) * 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP7812052B2 (ja) * 2020-09-01 2026-02-09 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
KR20240053617A (ko) 2021-08-30 2024-04-24 민드랭크 에이아이 리미티드 Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물

Also Published As

Publication number Publication date
CL2024002388A1 (es) 2025-01-24
MX2023008854A (es) 2023-10-17
JP2024505250A (ja) 2024-02-05
US20250154137A1 (en) 2025-05-15
ECSP23057029A (es) 2023-10-31
KR20230152011A (ko) 2023-11-02
CO2023011071A2 (es) 2023-11-10
JOP20230167A1 (ar) 2023-07-26
GEAP202616925A (en) 2026-06-10
IL304521A (en) 2023-09-01
AU2022212019A1 (en) 2023-08-03
US20230089073A1 (en) 2023-03-23
IL304521B1 (en) 2026-06-01
CA3209593A1 (en) 2022-08-04
WO2022165076A1 (en) 2022-08-04
EP4563199A2 (en) 2025-06-04
CN122344190A (zh) 2026-07-07
AU2022212019A9 (en) 2024-10-17
US20250092025A1 (en) 2025-03-20
US20240252492A1 (en) 2024-08-01
CL2023002204A1 (es) 2024-03-01
CR20230330A (es) 2023-11-15
GEP20267901B (en) 2026-06-10
BR112023015045A2 (pt) 2023-10-03
GEAP202316333A (en) 2023-12-11
US12459929B2 (en) 2025-11-04
EP4563199A3 (en) 2025-08-06
EP4284795A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
CU20220028A7 (es) Compuestos derivados sustituidos del anillo de imidazol fusionado
JP5542058B2 (ja) 抗糖尿病性三環式化合物
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
PE20081454A1 (es) Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor
PE20252338A1 (es) Compuesto agonista de receptor thrb y metodo de preparacion
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
TW202016073A (zh) B型肝炎蛋白殼組裝調節劑
PE20060921A1 (es) Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales
ECSP10010209A (es) Agonistas novedosos de los receptores de glucocorticoides
UY39944A (es) Compuestos espirocíclicos
PE20070854A1 (es) Compuestos heterociclos como agonistas del receptor de acido nicotinico
AR078495A1 (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico
CL2012000516A1 (es) Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros.
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
PE20191656A1 (es) Inhibidores de ip6k
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20201280A1 (es) Amidas de imidazopiridina sustituidas y su uso
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
AR055890A1 (es) Derivados de 7-amino-[1,3] tiazolo [4, 5-d] pirimidina 5-sustituida; su preparacion y composicion farmaceutica
PE20080191A1 (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
PE20040959A1 (es) Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
CO2023001367A2 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos
AR045720A1 (es) Derivados de pirrol 2,5 tio y oxo sustituidos como moduladores de receptores hormonales de higado
JP6066126B2 (ja) 新規化合物、医薬組成物及びその使用
WO2006078886A2 (en) Compounds and compositions as wnt signaling pathway modulators